Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Risdiplam
Drug ID BADD_D02592
Description Risdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA).[L12615] It increases systemic SMN protein concentrations by improving the efficiency of _SMN2_ gene transcription. This mechanism of action is similar to its predecessor [nusinersen], the biggest difference being their route of administration: nusinersen requires intrathecal administration, as does the one-time gene therapy [onasemnogene abeparvovec], whereas risdiplam offers the ease of oral bioavailability.[L15351,A216871] Risdiplam was approved by the FDA in August 2020 for use in patients 2 months of age or older in the treatment of spinal muscular atrophy (SMA).[L15331,L15336] Set to be substantially cheaper than other available SMA therapies,[L15351] risdiplam appears to provide a novel and relatively accessible treatment option for patients with SMA regardless of severity or type.
Indications and Usage Risdiplam is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.[L15336]
Marketing Status approved; investigational
ATC Code M09AX10
DrugBank ID DB15305
KEGG ID D11406
MeSH ID C000629884
PubChem ID 118513932
TTD Drug ID D0N5MH
NDC Product Code 50242-175
UNII 76RS4S2ET1
Synonyms Risdiplam | 7-(4,7-Diazaspiro(2.5)oct-7-yl)-2-(2,8-dimethylimidazo(1,2-b)pyridazin-6-yl)-4H-pyrido(1,2-a)pyrimidin-4-one
Chemical Information
Molecular Formula C22H23N7O
CAS Registry Number 1825352-65-5
SMILES CC1=CC(=NN2C1=NC(=C2)C)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(C5)CC6
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gastritis07.08.02.0010.004854%
Gastrointestinal disorder07.11.01.0010.022062%Not Available
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.0060.002206%
Hepatic steatosis14.08.04.005; 09.01.07.0030.004854%Not Available
Hyperhidrosis23.02.03.004; 08.01.03.0280.005957%
Hypertension24.08.02.0010.007060%
Hypoglycaemia14.06.03.001; 05.06.03.0010.003309%
Hypokalaemia14.05.03.0020.015443%
Hypoxia22.02.02.0030.005515%
Ileus07.13.01.0010.002206%
Loss of consciousness17.02.04.0040.002206%Not Available
Muscle twitching15.05.03.0050.015002%Not Available
Muscular weakness17.05.03.005; 15.05.06.0010.022062%
Myalgia15.05.02.0010.007501%
Nephrolithiasis20.04.01.0020.004412%
Pallor24.03.04.001; 23.03.03.031; 08.01.03.0320.004854%Not Available
Photosensitivity reaction23.03.09.0030.012354%
Pneumothorax22.05.02.0030.003309%
Proteinuria20.02.01.0110.003309%
Pyrexia08.05.02.0030.021179%
Renal disorder20.01.02.0020.002206%Not Available
Respiratory disorder22.02.07.0020.012575%Not Available
Respiratory distress22.02.01.0120.004412%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.011031%
Scoliosis15.10.04.0010.002206%
Seizure17.12.03.0010.003309%
Skin irritation23.03.04.0090.004854%Not Available
Sneezing22.12.03.0240.002206%
Somnolence19.02.05.003; 17.02.04.0060.008163%
Status epilepticus17.12.03.0050.002206%Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages